Neurotech reports further positive Phase 2/3 autism trial results
Neurotech reports further benefits from Phase 2/3 trial of NTI164 in autism patients Patients showed 56% improvement in CGI-S score from baseline at week 12 Patients unblinded at end of week eight showed 21% improvement in CGI-S score to week 12 …